Hormone replacement therapy: 1815.84 woman-years of follow-up main clinical events.
作者： Joaquín Cortés-Prieto , Maria Lina Vicente-Hernanz , Ana Cortés-García , Hugh Ahern
关键词:
摘要: BACKGROUND One hundred and eighty-five women with a mean age of 50.71 (SD=5.58) years upon initiation treatment were studied before, during, treatment. MATERIALS AND METHODS Included in the profile patients under study family personal histories, gynecological breast examinations. Population age: a) <60 years old, 171 (92.43%), b) aged 60 years or older, 14 (7.57%). Dosage comprised both 0.625 mg/daily orally conjugated equine estrogens 2.5 5 mg/daily medroxy progesterone acetate. No further specific was prescribed. Mean duration 9.82 (SD=5.42) for all women; 9.70 (SD=5.44) younger group. Follow-up 1815.84 woman-years, 5 over (76.75%) on 142 women. Fifty-two (28.11%) dropped out. RESULTS deaths occurred during Four cardiovascular events (2.16%) reported. spontaneous bone fracture documented. Nonetheless, there 12 fractures traumatic origin (6.48%), none them hip fractures. Five cancers observed. Likewise, one diagnosis cancer every 37 treated from our series evidenced. There 117 (63.24%) without any events. CONCLUSION A higher risk serious cannot be inferred statistical analysis more
sci-hub.se 参考文章(27)
Nachtigall Mj, Nachtigall Rd, Nachtigall Rh, Nachtigall Le, Smilen Sw, Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstetrics & Gynecology. ,vol. 80, pp. 827- 830 ,(1992)
Harald Seeger, Alfred O. Mueck, Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause? Experimental vs. clinical data. The Journal of Steroid Biochemistry and Molecular Biology. ,vol. 109, pp. 11- 15 ,(2008) , 10.1016/J.JSBMB.2007.12.002
Writing Group for the Women's Health Initiative Investigators, Writing Group for the Women's Health Initiative Investigators, None, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial JAMA. ,vol. 288, pp. 321- 333 ,(2002) , 10.1001/JAMA.288.3.321
Harald Seeger, Alfred O. Mueck, Are estradiol metabolites involved in gynaecological carcinogenesis Hormone Molecular Biology and Clinical Investigation. ,vol. 1, pp. 111- 116 ,(2010) , 10.1515/HMBCI.2010.015
Adam Ostrzenski, Katarzyna M. Ostrzenska, WHI clinical trial revisit: imprecise scientific methodology disqualifies the study's outcomes. American Journal of Obstetrics and Gynecology. ,vol. 193, pp. 1599- 1604 ,(2005) , 10.1016/J.AJOG.2005.07.085
Christopher I Li, Kathleen E Malone, Peggy L Porter, Noel S Weiss, Mei-Tzu C Tang, Kara L Cushing-Haugen, Janet R Daling, Relationship between long durations and different regimens of hormone therapy and risk of breast cancer JAMA. ,vol. 289, pp. 3254- 3263 ,(2003) , 10.1001/JAMA.289.24.3254
ROBERT D. NACHTIGALL, MARK E. BECKMAN, LILA E. NACHTIGALL, RICHARD H. NACHTIGALL, Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics & Gynecology. ,vol. 54, pp. 74- 79 ,(1979) , 10.1097/00006250-197907000-00017
Cecilia Magnusson, John A. Baron, Nestor Correia, Reinhold Bergstr�m, Hans-Olov Adami, Ingemar Persson, Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. International Journal of Cancer. ,vol. 81, pp. 339- 344 ,(1999) , 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6
John Eden, Progestins and breast cancer. American Journal of Obstetrics and Gynecology. ,vol. 188, pp. 1123- 1131 ,(2003) , 10.1067/MOB.2003.201
H. P. G. Schneider, The view of The International Menopause Society on the Women's Health Initiative Climacteric. ,vol. 5, pp. 211- 216 ,(2002) , 10.1080/CMT.5.3.211.216